Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

The goal of Part 1 of this clinical research study is to find the highest tolerable dose of ASTX029 that can be given in combination with ASTX727 to participants who have RAS-mutant MDS or MDS/MPN. The goal of Part 2 of this clinical research study is to learn if the dose of ASTX029 found in Part 1 can help to control the disease when used in combination with ASTX727.

Start Date31 Jan 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT06113289 / SuspendedPhase 1/2IIT

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

To find the recommended dose of the study drugs ASTX727 and ASTX029 that can be given to patients with relapsed/refractory AML. The goal of Part 2 of the study is to learn if the dose of study drugs found in Part 1B can help to control AML.

Start Date08 Feb 2024

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT04466514 / CompletedPhase 1

A Phase 1, 3-Way Crossover Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Open-label, single dose, randomized, three-period, crossover design study to evaluate the effect of food on the bioavailability of a single oral dose of ASTX029 in healthy adult male and female participants.
Following a screening period of up to 28 days, eligible participants will be enrolled and randomized to receive a single treatment (A, B, C) in a random order, with each treatment separated by an approximate 5-day washout period. The duration of the study is expected to be approximately 42 days.

Start Date23 Jul 2020

Sponsor / Collaborator

Astex Pharmaceuticals, Inc.

100 Clinical Results associated with Beroterkib

100 Translational Medicine associated with Beroterkib

100 Patents (Medical) associated with Beroterkib

Literatures (Medical) associated with Beroterkib

01 Oct 2021·Molecular Cancer TherapeuticsQ2 · MEDICINE

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK

Q2 · MEDICINE

Article

Author: Murray, Christopher W. ; Castro, Juan ; Rees, David C. ; Stanczuk, Lukas ; Martins, Vanessa ; O'Reilly, Marc ; Richardson, Caroline J. ; Rich, Sharna J. ; Thompson, Neil T. ; Reader, Michael ; Hindley, Christopher J. ; Kucia-Tran, Justyna ; Brothwood, Jessica L. ; East, Charlotte ; Muench, Sandra ; Norton, David ; Courtin, Aurélie ; Wallis, Nicola G. ; Heightman, Tom D. ; Woolford, Alison J.-A. ; Berdini, Valerio ; Munck, Joanne M. ; Shah, Alpesh D. ; Bevan, Luke ; Ferraldeschi, Roberta ; Wilsher, Nicola E. ; Lyons, John F.

AbstractThe MAPK signaling pathway is commonly upregulated in human cancers. As the primary downstream effector of the MAPK pathway, ERK is an attractive therapeutic target for the treatment of MAPK-activated cancers and for overcoming resistance to upstream inhibition. ASTX029 is a highly potent and selective dual-mechanism ERK inhibitor, discovered using fragment-based drug design. Because of its distinctive ERK-binding mode, ASTX029 inhibits both ERK catalytic activity and the phosphorylation of ERK itself by MEK, despite not directly inhibiting MEK activity. This dual mechanism was demonstrated in cell-free systems, as well as cell lines and xenograft tumor tissue, where the phosphorylation of both ERK and its substrate, ribosomal S6 kinase (RSK), were modulated on treatment with ASTX029. Markers of sensitivity were highlighted in a large cell panel, where ASTX029 preferentially inhibited the proliferation of MAPK-activated cell lines, including those with BRAF or RAS mutations. In vivo, significant antitumor activity was observed in MAPK-activated tumor xenograft models following oral treatment. ASTX029 also demonstrated activity in both in vitro and in vivo models of acquired resistance to MAPK pathway inhibitors. Overall, these findings highlight the therapeutic potential of a dual-mechanism ERK inhibitor such as ASTX029 for the treatment of MAPK-activated cancers, including those which have acquired resistance to inhibitors of upstream components of the MAPK pathway. ASTX029 is currently being evaluated in a first in human phase I–II clinical trial in patients with advanced solid tumors (NCT03520075).

26 Aug 2021·Journal of Medicinal ChemistryQ1 · MEDICINE

Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2

Q1 · MEDICINE

Article

Author: Howard, Steven ; Kucia-Tran, Justyna ; Walton, Hugh ; Day, James E. H. ; Rees, David C. ; Watts, John ; Palmer, Nicholas ; Courtin, Aurélie ; Wallis, Nicola G. ; Munck, Joanne M. ; Woolford, Alison J.-A. ; Reader, Michael ; Pathuri, Puja ; Buck, Ildiko M. ; Norton, David ; Berdini, Valerio ; Peakman, Torren M. ; Griffiths-Jones, Charlotte M. ; Bevan, Luke ; Rich, Sharna J. ; Martins, Vanessa ; Cooke, Michael ; Shannon, Jonathan ; Coyle, Joseph E. ; Shah, Alpesh ; Carr, Maria G. ; Fazal, Lynsey ; Muench, Sandra ; Onions, Stuart ; East, Charlotte ; O’Reilly, Marc ; Murray, Christopher W. ; Cousin, David ; Heightman, Tom D. ; Wilsher, Nicola E.

Aberrant activation of the mitogen-activated protein kinase pathway frequently drives tumor growth, and the ERK1/2 kinases are positioned at a key node in this pathway, making them important targets for therapeutic intervention. Recently, a number of ERK1/2 inhibitors have been advanced to investigational clinical trials in patients with activating mutations in B-Raf proto-oncogene or Ras. Here, we describe the discovery of the clinical candidate ASTX029 (15) through structure-guided optimization of our previously published isoindolinone lead (7). The medicinal chemistry campaign focused on addressing CYP3A4-mediated metabolism and maintaining favorable physicochemical properties. These efforts led to the identification of ASTX029, which showed the desired pharmacological profile combining ERK1/2 inhibition with suppression of phospho-ERK1/2 (pERK) levels, and in addition, it possesses suitable preclinical pharmacokinetic properties predictive of once daily dosing in humans. ASTX029 is currently in a phase I-II clinical trial in patients with advanced solid tumors.

100 Deals associated with Beroterkib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 3	US	Astex Pharmaceuticals, Inc.	10 May 2018
Advanced Malignant Solid Neoplasm	Phase 2	GB	Taiho Oncology, Inc.	10 May 2018
Advanced Malignant Solid Neoplasm	Phase 2	FR	Taiho Oncology, Inc.	10 May 2018
Advanced Malignant Solid Neoplasm	Phase 2	ES	Taiho Oncology, Inc.	10 May 2018
Advanced Malignant Solid Neoplasm	Phase 2	US	Taiho Oncology, Inc.	10 May 2018
Acute Myeloid Leukemia	Phase 1	US	Astex Pharmaceuticals, Inc.	14 Nov 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03520075 (ESMO2024) Manual	Phase 1/2	MAPK positive Neoplasms genomic alterations in the MAPK pathway	32	ASTX029	(uxaxjsrjuv) = xonleuraao ptoepugseg (nywvhkjwvk, 1.0 - 24.0) View more	Positive	14 Sep 2024
ASH2023	Not Applicable	Acute Myeloid Leukemia	-	ASTX029	(mxjmtgehit) = yilszezaim dvnncjydln (jqyicdlzwf )	-	10 Dec 2023
ASH2023	Not Applicable	Acute Myeloid Leukemia	-	Venetoclax	(mxjmtgehit) = dobfnabtln dvnncjydln (jqyicdlzwf )	-	10 Dec 2023
NCT03520075 (ASCO2022) Manual	Phase 1	Solid tumor KRAS Mutation	76	ASTX 029 (Phase 1A)	(vimqpmlzqp) = tsgqojkikq mqllwbvtzu (knznixncnc ) View more	Positive	02 Jun 2022
NCT03520075 (ASCO2022) Manual	Phase 1	Solid tumor KRAS Mutation	76	ASTX 029 (Phase 1B)	(txuzpkglix) = erwohggedv ekdekpqldo (djsvpllbzt )	Positive	02 Jun 2022
NCT03520075 (AACR2021) Manual	Phase 1	Solid tumor	56	ASTX029	(xtuzbnmgsm) = 1/6 at the 200 mg dose level（Cohort 5, PiB/fed）（grade 3 maculopapular rash）；1 pt at the 280 mg dose level（Cohort 12, tablet/fasting）（grade 2 central serous retinopathy） hubbfhgiie (pdfdctfqcj ) View more	Positive	01 Jul 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Beroterkib

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation